Association of BNP and Troponin Levels with Outcome among Cardiac Resynchronization Therapy Recipients
暂无分享,去创建一个
Jagmeet P. Singh | S. Saba | A. Kadish | G. Fonarow | W. Abraham | J. Gorcsan | A. Maisel | A. Shalaby | M. Bersohn | Li-Yin Lee | Jasmina Halilovic | A. Sonel
[1] S. Solomon,et al. Brain Natriuretic Peptide and Cardiac Resynchronization Therapy in Patients With Mildly Symptomatic Heart Failure , 2013, Circulation. Heart failure.
[2] S. Aakhus,et al. Prognostic value of cardiac troponin T in patients with moderate to severe heart failure scheduled for cardiac resynchronization therapy. , 2011, American heart journal.
[3] Wojciech Zareba,et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. , 2009, The New England journal of medicine.
[4] M. Gold,et al. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. , 2009, Journal of the American College of Cardiology.
[5] A. Shalaby,et al. Usefulness of Brain Natriuretic Peptide Level at Implant in Predicting Mortality in Patients with Advanced But Stable Heart Failure Receiving Cardiac Resynchronization Therapy , 2009, Clinical cardiology.
[6] Stefano Ghio,et al. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. , 2008, Journal of the American College of Cardiology.
[7] N. Freemantle,et al. Predicting the long-term effects of cardiac resynchronization therapy on mortality from baseline variables and the early response a report from the CARE-HF (Cardiac Resynchronization in Heart Failure) Trial. , 2008, Journal of the American College of Cardiology.
[8] E. Fleck,et al. Functional capacity and changes in the neurohormonal and cytokine status after long-term CRT in heart failure patients. , 2007, International journal of cardiology.
[9] Nick Freemantle,et al. Predictors and treatment response with cardiac resynchronization therapy in patients with heart failure characterized by dyssynchrony: a pre-defined analysis from the CARE-HF trial. , 2007, European heart journal.
[10] M. Zahid,et al. Detectable Troponin Levels Predict Poor Prognosis in Patients With Left Ventricular Dysfunction Undergoing Internal Defibrillator Implantation , 2007, Pacing and clinical electrophysiology : PACE.
[11] J. Daubert,et al. Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony. , 2006, European heart journal.
[12] G. Fonarow,et al. Usefulness of preimplantation B-type natriuretic peptide level for predicting response to cardiac resynchronization therapy. , 2007, American Journal of Cardiology.
[13] J. Kautzner,et al. Decrease in plasma B‐type natriuretic peptide early after initiation of cardiac resynchronization therapy predicts clinical improvement at 12 months , 2006, European journal of heart failure.
[14] B. Radovancević,et al. Brain natriuretic peptide levels and response to cardiac resynchronization therapy in heart failure patients. , 2006, Congestive heart failure.
[15] C. Forleo,et al. Prognostic value of brain natriuretic peptide in the management of patients receiving cardiac resynchronization therapy , 2006, European journal of heart failure.
[16] R. Strasser,et al. Long term biventricular resynchronisation therapy in advanced heart failure: effect on neurohormones , 2005, Heart.
[17] D. DeMets,et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. , 2004, The New England journal of medicine.
[18] Gabriel Thabut,et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. , 2004, Journal of the American College of Cardiology.
[19] G. Fonarow,et al. Cardiac Troponin I Is Associated With Impaired Hemodynamics, Progressive Left Ventricular Dysfunction, and Increased Mortality Rates in Advanced Heart Failure , 2003, Circulation.
[20] D. Delurgio,et al. Effect of Cardiac Resynchronization Therapy on Left Ventricular Size and Function in Chronic Heart Failure , 2003, Circulation.
[21] J. Healey,et al. Prognostic use of cardiac troponin T and troponin I in patients with heart failure. , 2003, The Canadian journal of cardiology.
[22] P. Hanrath,et al. Usefulness of brain natriuretic peptide release as a surrogate marker of the efficacy of long-term cardiac resynchronization therapy in patients with heart failure. , 2003, The American journal of cardiology.
[23] G. Fonarow,et al. Combining natriuretic peptides and necrosis markers in determining prognosis in heart failure. , 2003, Reviews in cardiovascular medicine.
[24] RudolfBerger,et al. B-Type Natriuretic Peptide Predicts Sudden Death in Patients With Chronic Heart Failure , 2002 .
[25] H. Naruse,et al. Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. , 2002, The American journal of cardiology.
[26] M. Vogeser,et al. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. , 2001, Journal of the American College of Cardiology.
[27] H. Kishida,et al. Clinical significance of elevated levels of cardiac troponin T in patients with chronic heart failure. , 1999, The American journal of cardiology.
[28] M. Kinoshita,et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. , 1998, American heart journal.